Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.
This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
📻 Siste episoder av COR2ED - Oncology Medical Conversation
Her er de nyeste episodene tilgjengelige via RSS-feeden:
Laster episoder...
📱 Slik abonnerer du på COR2ED - Oncology Medical Conversation
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification (00:25:03)
Understanding HER2-low and HER2-ultralow classification in mBC
In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...
Understanding EP-NEC: Through Diagnosis, Treatment, and Support (00:27:28)
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...
Exploring the role of targeted radiopharmaceutical treatment in NETs (00:21:56)
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...
Tackling mPDAC: chemotherapy strategies that matter (00:21:51)
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...
Understanding Rare NSCLC Mutations: Insights, access and support (00:20:34)
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...
The HER2 diagnostic and treatment landscape in NSCLC (00:18:36)
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...
The HER2 Diagnostic and Treatment Landscape in NSCLC (00:21:27)
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses (00:13:43)
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therap...
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer (00:26:05)
This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing met...
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions (00:11:28)
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Key clinical takeaways:
MMR status should be tested in all patients at diagnosis and upon disease progre...
Intermediate HCC – The evolving role of IO (00:27:12)
Intermediate HCC – The evolving role of IO
In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion ...
Intermediate HCC – treatment options and strategies (00:20:19)
In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore t...
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch (00:26:18)
Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dive...
Testing to treatment of BRAF-mutant metastatic NSCLC (00:23:25)
Testing to treatment of BRAF-mutant metastatic NSCLC
In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metast...
HCC podcast series part 1: The use of IO in unresectable HCC (00:23:21)
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep di...
BRAF-mutated CRC: testing to treatment (00:25:50)
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.
...
In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between ...
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication a...
Regional differences in NET: Treatment and future developments (00:21:16)
In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field ...
Regional differences in NET: Epidemiology, diagnosis, and referral strategies (00:21:47)
In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future d...
Understanding the needs of different patient populations in colorectal cancer (00:25:30)
Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger pati...
Interpreting real-world evidence in later-line mCRC (00:27:54)
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?
In ...
Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores (00:32:21)
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Usted está viendo el te...
Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores (00:32:21)
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte...
Cáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores (00:29:54)
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte...
Side 1 av 2
COR2ED - Oncology Medical Conversation - Gratis RSS Feed for Norsk Podcast | OpenPodMe | OpenPodMe - Åpen RSS for Norske Podcaster
